VICORE PHARMA HOLDING - Key Persons
Job Titles:
- CEO
- CEO since 2018
- Venture Partner at HealthCap
Hans Jeppsson has a cross-disciplinary background in finance and medicine. He has previously worked as a biotech analyst at Danske Bank as well as within preclinical research at AstraZeneca R&D.
Carl-Johan Dalsgaard has been a Venture Partner at HealthCap since 2000, thereby he has served as CEO of several companies in which HealthCap has invested. Prior to that, he has ten years of experience from senior positions within the AstraZeneca Group, such as pre-clinical research director, therapeutic area manager of pain and anesthesia, CEO of Astra Pain Control AB and part of the Group's research management team.
Job Titles:
- VP Clinical Development since 2020
Elin Rosendahl has more than 20 years' experience of managing global biopharmaceutical development programs and leading cross-functional teams. Solid experience of all phases of clinical drug development with focus on design of innovative and patient-focused paths to market, effective management of global, cross-functional teams and optimized collaborations with contract research organizations (CROs)
Hans Jeppsson has a cross-disciplinary background in finance and medicine. He has previously worked as a biotech analyst at Danske Bank as well as within preclinical research at AstraZeneca R&D.
Job Titles:
- Member of the Board of Directors
- Board Member since 2018
Mr. Schikan is former CEO of Prosensa (acquired by BioMarin). His previous assignments include leadership roles at Genzyme (acquired by Sanofi) and Organon (acquired by Schering Plough). He previously served on the boards of Hansa Biopharma, Asceneuron, Wilson Therapeutics (acquired by Alexion), Swedish Orphan Biovitrum, Sweden and Therachon (acquired by Pfizer).
Job Titles:
- Member of the Board of Directors
- Board Member since 2020
(born 1958) has more than 25 years of experience from leading positions in different roles within pharmaceutical development and commercialization. She has worked strategically and operationally from clinical and commercial development to launch execution. Her leadership experience spans alliance management, investment risk mitigation, global clinical and commercial management, new business strategy development, product launch, and business sustainability. Heidi has a unique, multicultural and global experience of engaging people from different cultures to work towards the same vision and goals.
Holdings in Vicore: None
Job Titles:
- Member of the Board of Directors
- Chairman of the Board since 2022. Board Member
Jacob Gunterberg is a former partner at HealthCap and has extensive experience in venture capital investment operations and corporate finance in life science. Jacob Gunterberg has long experience as board member in both private and publicly traded companies.
Job Titles:
- Director of Digital Therapeutics since 2021
Jessica Shull has more than 20 years' experience in the field of digital technologies for healthcare including development of virtual surgical devices. She is considered an authority in HTA requirements for patient-facing software and innovation adoption in Europe and internationally. In previous roles she worked on digital health best practices for the WHO and with the Digital Therapeutics Alliance she focused on digital therapeutic product integration, regulation, and policy. Shareholdings: - Options: - 50,000 Education: MA, MSc, PhD candidate Biomedicine 2022
Job Titles:
- Chief Scientific Officer since 2018
has more than 20 years of experience from heading research teams and managing drug discovery projects in both big pharma and startups. Johan gained his MD, PhD and Associate Professorship at Karolinska Institutet and Vanderbilt University.
Job Titles:
- Head of Preclinical Development
Johanna has a Ph.D and expertise in pharmaceutical metabolism. She has extensive experience in preclinical interpretation and is responsible for drug development projects.
Job Titles:
- Member of the Board of Directors
- Board Member of Toleranzia AB
- Board Member since 2018
has extensive experience in biomedicine and has, among others, held a senior position at AstraZeneca AB where he was responsible for the research and development of medicines for respiratory, inflammatory and autoimmune symptoms. Maarten is currently CMO at AM-Pharma a clinical stage Biotech.
Mikael Nygård has extensive experience from Business Development in the healthcare industry. He has led M&A and Corporate Development at the care provider Humana AB and has also worked in the global healthcare team at the strategy consulting firm Boston Consulting Group.
Job Titles:
- Chief Administrative Officer since 2009
Nina has more than 15 years' experience of working with marketing and communication in the pharmaceutical industry.
Rohit Batta has over 20 years of experience as a medical doctor with an extensive background leading medical and clinical development teams whilst developing drugs for rare diseases. His previous roles include senior level positions within Cell and Gene Therapy at GlaxoSmithKline leading the clinical development and defining the clinical strategy for haemoglobinopathy gene therapy medicines. He also led the global medical and late stage clinical development teams to launch the world's first gene therapy for patients with a paediatric rare disease. Rohit holds an MBBS from Kings College London where he is currently a Senior Visiting Lecturer.
Job Titles:
- Member of the Board of Directors
- Board Member since 2018
- External Managing Director of MetaboGen AB
- Managing Director of MetaboGen AB
Sara Malcus has more than ten years of experience from operational management and board work through her work with developing early drug projects at GU Ventures, Astra Zeneca AB and in smaller start-up companies.
Åsa Magnusson - Chief Commercial Officer
Åsa Magnusson has more than 20 years of experience as a commercial executive in the pharmaceutical industry with focus on securing market access and launching rare disease medicines. Her previous roles include leading cross-functional teams as General Manager at Arvelle and in different senior commercial roles at Alexion, expanding innovative antibody products and heading the commercial launch of Actelion's pulmonary arterial hypertension (PAH) pharmaceuticals.
Mikael Nygård has extensive experience from Business Development in the healthcare industry. He has led M&A and Corporate Development at the care provider Humana AB and has also worked in the global healthcare team at the strategy consulting firm Boston Consulting Group.